Summary of Significant Accounting Policies (Details) (USD $)	3 Months Ended		9 Months Ended			3 Months Ended		9 Months Ended				3 Months Ended	9 Months Ended	3 Months Ended	9 Months Ended		9 Months Ended
	Sep. 30, 2013	Sep. 30, 2012	Sep. 30, 2013 Segment	Sep. 30, 2012	Dec. 31, 2012	Sep. 30, 2013 Neovasc [Member]	Sep. 30, 2012 Neovasc [Member]	Sep. 30, 2013 Neovasc [Member]	Sep. 30, 2012 Neovasc [Member]	Sep. 30, 2013 Pharmaceutical [Member] Segment	Sep. 30, 2013 Diagnostics [Member] Segment	Sep. 30, 2013 Research and Development Expense [Member]	Sep. 30, 2013 Research and Development Expense [Member]	Sep. 30, 2013 Pharmsynthez [Member]	Sep. 30, 2013 Pharmsynthez [Member]	Apr. 30, 2013 Pharmsynthez [Member]	Sep. 30, 2013 Rxi Pharmaceuticals Corporation [Member]
Summary of Significant Accounting Policies [Line Items]
Reduction of research and development expense from equity based compensation expense												$ 2,700,000	$ 2,700,000
Reduction of research and development expense from equity based compensation expense (usd per share)												$ 0.01	$ 0.01
Goodwill and intangible assets	1,100,000,000		1,100,000,000		200,000,000
Revenue from services	2,770,000	100,000	9,050,000	332,000		200,000	100,000	600,000	300,000
Revenue from transfer of intellectual property	1,308,000	200,000	16,080,000	400,000
Revenue related to sale of intellectual property			12,500,000	0													12,500,000
Revenue related to our license agreements														1,300,000	3,200,000
Total deferred revenue related to other revenues	7,900,000		7,900,000		1,900,000											9,500,000
Allowance for doubtful accounts receivable	1,134,000		1,134,000		474,000
Equity-based compensation expense for continuing operations	$ 400,000	$ 1,100,000	$ 7,411,000	$ 3,281,000
Number of reportable segments			2
Number of operating segments										2	2